Pulmonary Fibrosis News and Research

RSS

How does COVID-19 affect patients with idiopathic pulmonary fibrosis?

A new study discusses the outcomes of idiopathic pulmonary fibrosis patients with confirmed SARS-CoV-2 infection.

6 Mar 2022

Phase I clinical trial evaluates AI-discovered first anti-fibrotic small molecule inhibitor

Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that it has dosed multiple healthy volunteers in Phase I clinical trial evaluating ISM001-055, the first anti-fibrotic small molecule inhibitor generated by Insilico's AI-powered drug discovery platform for idiopathic pulmonary fibrosis (IPF).

24 Feb 2022

Cardiopulmonary limitations six months after surviving COVID-19

A recent prospective cohort study assessed the cardiopulmonary effects in patients six months after COVID-19 infection.

23 Feb 2022

Mouse-adapted virus model to study persistent COVID induced lung disease

Researchers develop a mouse model to identify early biomarkers and test countermeasures needed to detect and prevent PASC.

21 Feb 2022

Biochemical changes in lung physiology not responsible for severe clinical outcomes in the older population

Researchers investigated whether age-dependent changes in lung physiology make the elderly disproportionately susceptible to SARS-CoV-2 infection.

21 Feb 2022

Study suggests tea polyphenols may modulate COVID-19 via intestinal microbiota

A new study discusses the state of current knowledge about the potential use of tea polyphenols in the prevention and treatment of COVID-19.

16 Feb 2022

Incomplete repair of the damaged lung may contribute to death from COVID-19 and non-COVID ARDS

Investigators studying lung cells have discovered that the normal repair process that occurs after lung disease or injury appears to be incomplete but still ongoing in patients who died of COVID-19 and non-COVID acute respiratory distress syndrome (ARDS).

15 Feb 2022

Study shows positive outcomes in COVID-19 patients who underwent lung transplants

For many COVID-19 patients with irrecoverable lung damage, transplantation is the only option for survival. However, there is limited information about the long-term outcomes of these patients, including postoperative complications, hospital length of stay and survival.

3 Feb 2022

New RNA therapies for the treatment of heart failure and organ fibrosis

RNA has already been making an impact in the context of the vaccine program, but the potential of RNA-based compounds is far from being fully tapped, as RNA allows for entirely new therapeutic approaches.

1 Feb 2022

Scientists discover new insights about lymphangioleiomyomatosis

Researchers have discovered new insights about lymphangioleiomyomatosis (LAM), a rare lung disease, which affects about 1 in 200,00 Americans and commonly features the growth of abnormal cells in different tissues and organs, including the lungs.

1 Feb 2022

Prion-like domains in SARS-CoV-2 RBD and ACE2 play important functional roles in viral adhesion and entry

Scientists have recently detected and analyzed viral PrDs in the S protein of SARS-CoV-2, which are the novel regulators of virion assembly.

31 Jan 2022

Cedars-Sinai experts conduct a national analysis on COVID-19 lung transplants

The analysis of more than 3,000 lung transplants in the U.S. between Aug. 1, 2020, and Sept. 30, 2021, showed that during the pandemic, 7% of the nation's lung transplants were performed to treat severe, irreversible lung damage caused by COVID-19. More than half of these patients needed ventilators or extracorporeal membrane oxygenation, or ECMO, before their transplant.

27 Jan 2022

Exploring the relationship between stem cells and COVID-19

Though COVID-19-related stem cell clinical research is still in its infancy, stem cell treatment offers extensive clinical application possibilities and a far-reaching relevance thanks to ongoing exploration of stem cell clinical research and data mining.

14 Jan 2022